Marion Harris

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

Medicine, Oncology, Pharmacology +13

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie, Joshua D. Cohen, Kamel Lahouel et al. · New England Journal of Medicine · 2022 · 976 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

Belinda Lee, Lara Lipton, Joshua D. Cohen et al. · Annals of Oncology · 2019 · 213 citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized phase III study of weekly <i>nab</i>-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · Journal of Clinical Oncology · 2013 · 116 citations

Medicine, Oncology, Pharmacology +12